

Counterpoint: Intensive Glucose Control and Mortality Clues

Diabetes Care

33, 2722-2724

DOI: [10.2337/dc10-1658](https://doi.org/10.2337/dc10-1658)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. American Journal of Medicine, 2011, 124, 993-996.	1.5	114
2	ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management, 2011, 1, 389-396.	0.5	0
3	Making sense of outcomes in the ACCORD trial. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 102-103.	0.2	1
4	Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Current Medical Research and Opinion, 2011, 27, 13-20.	1.9	170
5	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012, 25, 154-171.	1.0	28
6	Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT study. Current Medical Research and Opinion, 2012, 28, 503-511.	1.9	6
7	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. European Heart Journal, 2012, 33, 1049-1057.	2.2	19
8	Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2100-2107.	8.6	49
9	Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. Cardiovascular Diabetology, 2012, 11, 69.	6.8	13
10	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2012, 35, 1364-1379.	8.6	3,077
11	Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2012, 13, 553-563.	1.8	19
12	Prise en charge de lâ€™hyperglycÃ©mie chez le patient diabÃ©tique de type 2 : une stratÃ©gie centrÃ©e sur le patient. Medecine Des Maladies Metaboliques, 2012, 6, III-XXV.	0.1	2
13	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012, 55, 1577-1596.	6.3	1,718
14	Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes. Current Atherosclerosis Reports, 2013, 15, 351.	4.8	24
15	Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes. American Journal of Medicine, 2013, 126, S38-S48.	1.5	118
16	Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema. , 2013, , 940-968.		23
17	Linagliptin for the treatment of Type 2 diabetes. Diabetes Management, 2014, 4, 85-101.	0.5	2
18	Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs, 2014, 19, 571-601.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. <i>Lancet, The</i> , 2014, 384, 1936-1941.	13.7	134
20	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	8.6	33
21	Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. <i>Biomarkers in Medicine</i> , 2016, 10, 1153-1166.	1.4	10
22	Closing the Loop. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-29-S-42.	4.4	9
23	Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S176-S183.	3.6	104
24	Approach to diabetes management in patients with CVD. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 165-179.	4.9	38
25	The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 858-866.	1.8	33
26	Closing the Loop. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-27-S-41.	4.4	7
27	How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-27-S-36.	4.4	56
28	Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2018, 41, 604-612.	8.6	51
29	Glucose monitoring in diabetes: from clinical studies to real-world practice. <i>Practical Diabetes</i> , 2019, 36, 57-62.	0.3	2
30	Diabetes: the place of new therapies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880759.	3.2	10
31	Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2019, 42, 157-163.	8.6	86
32	Predicting 5- and 10-Year Mortality Risk in Older Adults With Diabetes. <i>Diabetes Care</i> , 2020, 43, 1724-1731.	8.6	25
33	Evolution of Type 2 Diabetes Management from a Gluco-centric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. <i>Drugs</i> , 2021, 81, 1373-1379.	10.9	13
34	Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review. <i>Diabetes Therapy</i> , 2023, 14, 823-838.	2.5	1